Author: admin

Intravenous Glibenclamide Reduces Lesional Water Uptake in Large Hemispheric Infarction

Prior studies have shown a linear relationship between computed tomography (CT)-derived radiodensity and water uptake, or brain edema, within stroke lesions. To test the hypothesis that intravenous glibenclamide (glyburide; BIIB093) reduces ischemic brain water uptake, we quantified the lesional net water uptake (NWU) on serial CT scans from patients enrolled in the phase 2 GAMES-RP Trial (Glyburide Advantage in Malignant Edema and Stroke).

Prior studies have shown a linear relationship between computed tomography (CT)-derived radiodensity and water uptake, or brain edema, within stroke lesions. To test the hypothesis that intravenous glibenclamide (glyburide; BIIB093) reduces ischemic brain water uptake, we quantified the lesional net water uptake (NWU) on serial CT scans from patients enrolled in the phase 2 GAMES-RP Trial (Glyburide Advantage in Malignant Edema and Stroke).

Association of Biologic Therapy With Coronary Inflammation in Patients With Psoriasis as Assessed by Perivascular Fat Attenuation Index

Psoriasis is a chronic inflammatory skin disease associated with increased coronary plaque burden and cardiovascular events. Biologic therapy for psoriasis has been found to be favorably associated with luminal coronary plaque, but it is unclear whether these associations are attributable to direct anti-inflammatory effects on the coronary arteries.

Psoriasis is a chronic inflammatory skin disease associated with increased coronary plaque burden and cardiovascular events. Biologic therapy for psoriasis has been found to be favorably associated with luminal coronary plaque, but it is unclear whether these associations are attributable to direct anti-inflammatory effects on the coronary arteries.

Uncontrolled Diabetes

A 51-year-old male patient with type 2 diabetes (T2DM) takes metformin 1000 mg twice daily, glipizide 10mg twice daily, and NPH insulin (35 units in the morning and 10 units in the evening). Despite all the meds, the patient still has frequent hyperglycemic reactions.

A 51-year-old male patient with type 2 diabetes (T2DM) takes metformin 1000 mg twice daily, glipizide 10mg twice daily, and NPH insulin (35 units in the morning and 10 units in the evening). Despite all the meds, the patient still has frequent hyperglycemic reactions.